Abstract:The 4-anilinoquinazoline scaffold has been historically used for designing EGFR/VEGFR/HER2 inhibitors while it has not been reported widely for developing c-Src inhibitors. Thus, a series of novel 4-anilinoquinazoline derivatives grafting different amide moieties at the 6-position were designed and synthesized as potential inhibitors for c-Src. In this manuscript, all of the designed compounds were screened via molecular docking using Discovery Studio 3.5 software. As expected, the results of the docking study revealed that most of these targeted compounds possessed lower binding energy than the positive control Saracatinib. Subsequently, all of the screened compounds were synthesized and evaluated for their c-Src in vitro inhibitory activities and in vitro antiproliferation assays against four human cancer cells (A549, MCF-7, HepG-2, HeLa). Among these compounds, 24 exhibited the most potent inhibitory activity against c-Src kinase as well as at the cellular level, of which the IC50 value reached up to 2.9 nM, comparable to the positive compound Saracatinib. Kinase selectivity profile also demonstrated that compound 24 showed good selectivity over several close kinase targets. These results, along with relative 3D-QSAR study, could provide an important basis for further development of compound 24 as a potent tyrosine kinase inhibitor.

Structure-Activity Relationship (sar) Studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of Potential Substrate-Specific Erk1/2 Inhibitors

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Design, synthesis and SAR of novel 7-azaindole derivatives as potential Erk5 kinase inhibitor with anticancer activity

Design, Synthesis, and Structure Activity Relationship (SAR) Studies of Novel Imidazo[1,2-A] Pyridine Derivatives As Nek2 Inhibitors

Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors

Structure-based design and synthesis of 5-benzyl-2-phenylpyrimidin-4(3H)-one derivatives as novel MEK1 inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Biological Evaluation and Structure Modification of (S)-3-aminopyrrolidine Derivatives

Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N'-phenylureas and thioureas as antitumor agents.

Design,synthesis and Biological Evaluation of 3H-Pyrano[2,3-d]pyrimidine-4, 7-Dionederivatives As MEK Inhibitors

Structure-activity Relationship Investigation for Benzonaphthyridinone Derivatives As Novel Potent Bruton's Tyrosine Kinase (BTK) Irreversible Inhibitors.

Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.

Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

Design, Synthesis, and Evaluation of Substituted 6-Amide-4-anilinoquinazoline Derivatives As C-Src Inhibitors

Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations

Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.

Design, Synthesis and Biological Evaluation of Novel 4-Anilinoquinazolines with C-6 Urea-Linked Side Chains As Inhibitors of the Epidermal Growth Factor Receptor.